Cargando…
Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects
Paediatric sarcomas are a heterogeneous group of disorders constituting bone sarcoma and various soft tissue sarcomas. Almost one-third of these presents with metastasis at baseline and another one-third recur after initial curative treatment. There is a huge unmet need in this cohort in terms of cu...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293381/ https://www.ncbi.nlm.nih.gov/pubmed/32606731 http://dx.doi.org/10.2147/OTT.S193363 |
_version_ | 1783546291471515648 |
---|---|
author | Pushpam, Deepam Garg, Vikas Ganguly, Sandip Biswas, Bivas |
author_facet | Pushpam, Deepam Garg, Vikas Ganguly, Sandip Biswas, Bivas |
author_sort | Pushpam, Deepam |
collection | PubMed |
description | Paediatric sarcomas are a heterogeneous group of disorders constituting bone sarcoma and various soft tissue sarcomas. Almost one-third of these presents with metastasis at baseline and another one-third recur after initial curative treatment. There is a huge unmet need in this cohort in terms of curative options and/or prolongation of survival. In this review, we have discussed the current treatment options, challenges and future strategies of managing relapsed/refractory paediatric sarcomas. Upfront risk-adapted treatment with multidisciplinary management remains the main strategy to prevent future recurrence or relapse of the disease. In the case of limited local and/or systemic relapse or late relapse, initial multimodality management can be administered. In treatment-refractory cases or where cure is not feasible, the treatment options are limited to novel therapeutics, immunotherapeutic approach, targeted therapies, and metronomic therapies. A better understanding of disease biology, mechanism of treatment refractoriness, identifications of driver mutation, the discovery of novel targeted therapies, cellular vaccine and adapted therapies should be explored in relapsed/refractory cases. Close national and international collaboration for translation research is needed to fulfil the unmet need. |
format | Online Article Text |
id | pubmed-7293381 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-72933812020-06-29 Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects Pushpam, Deepam Garg, Vikas Ganguly, Sandip Biswas, Bivas Onco Targets Ther Review Paediatric sarcomas are a heterogeneous group of disorders constituting bone sarcoma and various soft tissue sarcomas. Almost one-third of these presents with metastasis at baseline and another one-third recur after initial curative treatment. There is a huge unmet need in this cohort in terms of curative options and/or prolongation of survival. In this review, we have discussed the current treatment options, challenges and future strategies of managing relapsed/refractory paediatric sarcomas. Upfront risk-adapted treatment with multidisciplinary management remains the main strategy to prevent future recurrence or relapse of the disease. In the case of limited local and/or systemic relapse or late relapse, initial multimodality management can be administered. In treatment-refractory cases or where cure is not feasible, the treatment options are limited to novel therapeutics, immunotherapeutic approach, targeted therapies, and metronomic therapies. A better understanding of disease biology, mechanism of treatment refractoriness, identifications of driver mutation, the discovery of novel targeted therapies, cellular vaccine and adapted therapies should be explored in relapsed/refractory cases. Close national and international collaboration for translation research is needed to fulfil the unmet need. Dove 2020-06-08 /pmc/articles/PMC7293381/ /pubmed/32606731 http://dx.doi.org/10.2147/OTT.S193363 Text en © 2020 Pushpam et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Review Pushpam, Deepam Garg, Vikas Ganguly, Sandip Biswas, Bivas Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects |
title | Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects |
title_full | Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects |
title_fullStr | Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects |
title_full_unstemmed | Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects |
title_short | Management of Refractory Pediatric Sarcoma: Current Challenges and Future Prospects |
title_sort | management of refractory pediatric sarcoma: current challenges and future prospects |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7293381/ https://www.ncbi.nlm.nih.gov/pubmed/32606731 http://dx.doi.org/10.2147/OTT.S193363 |
work_keys_str_mv | AT pushpamdeepam managementofrefractorypediatricsarcomacurrentchallengesandfutureprospects AT gargvikas managementofrefractorypediatricsarcomacurrentchallengesandfutureprospects AT gangulysandip managementofrefractorypediatricsarcomacurrentchallengesandfutureprospects AT biswasbivas managementofrefractorypediatricsarcomacurrentchallengesandfutureprospects |